MarketPulse

weight loss

12 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly Phases Out Select European Insulin Products by 2027

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.
LLYweight lossEurope
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.
GPCRPhase 2 clinical trialFDA approval
BenzingaBenzinga··Vandana Singh

AbbVie's Obesity Drug Shows Promise With Up to 10% Weight Loss in Early Trial

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.
ABBVXLVIYHclinical trialweight loss
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk's Obesity Drug Underperforms Rival Zepbound in Late-Stage Trial

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.
LLYNVOclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Roche

Roche's Weight-Loss Drug Shows Promise With Double-Digit Results in Phase II Trial

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.
RHHBYZLDPYclinical resultsweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.
PFELLYNVORHHBYAZN+2GLP-1 drugsoral small-molecule
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss
The Motley FoolThe Motley Fool··Emma Newbery

Novo Nordisk Shares Slide on CagriSema Trial Results

Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.
LLYNVSNVOweight losstirzepatide
BenzingaBenzinga··Vandana Singh

Viking Therapeutics Climbs on Competitive Positioning in Obesity Drug Race

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.
LLYNVORHHBYVKTXPhase 3 trialsweight loss